GERMANTOWN, Wis.--(BUSINESS WIRE)-- Cambridge Major Laboratories, Inc. (CML or the Company) today announced the promotion of the Company’s Chief Business Officer, Brian W. Scanlan, to the position of President and Chief Executive Officer. He replaces Dr. Michael Major, the Company’s founder and CEO for the past 11 years, who has decided to retire.
Dr. Major has provided exceptional leadership and technical oversight to CML since its inception in 1999, and he will remain as non-executive Chairman and Scientific Advisor.
Scanlan joined CML in 2002, and was instrumental, working with Dr. Major to build the Company into one of the leading US-based pharmaceutical chemistry organizations. Their unique combination of scientific prowess and business savvy resulted in consistent growth and performance of the Company even during recent market turbulence.
Over the past nine years, Scanlan has taken on roles of increasing responsibility within the organization, most recently as Chief Business Officer where he was responsible for all business related aspects, sales/marketing, strategic planning, and Company resource allocation. He has been an active member of the Company’s board of directors the past four years. In his new role, he will have responsibility for all of CML’s operations in the US and Europe.
“I want to express my sincere thanks to all of the past and present employees of the Company, for their commitment and help in achieving this unprecedented growth,” said Dr. Major. “The Company grew from a small research lab to a highly sophisticated API manufacturing organization, and now requires a new talent to bring it to the next level. Brian is uniquely qualified, and I am convinced that Brian will fulfill all of the expectations. I wish him a lot of success.”
“I look forward to leading CML into the future,” said Scanlan. “It has been an honor to work alongside Michael these past nine years. He is one of the most gifted entrepreneurs I have ever met. I will ensure that CML continues its long-standing reputation for technical excellence, service, and responsiveness. We will continue to invest in the best people and cutting edge technologies to stay ahead of our competition, and better serve our customers.”
Cambridge Major Laboratories, Inc. is a leading global chemistry outsourcing partner to the pharmaceutical and biotechnology industries. The Company produces pharmaceutical intermediates and Active Pharmaceutical Ingredients (API), from early preclinical development to commercial manufacture. Operating from FDA inspected facilities in the US and Europe, CML is organized along five key Centers of Excellence including; Process Chemistry, GMP Manufacturing, Solid State Chemistry, Analytical Services, and Quality/Regulatory Compliance. Visit us at www.c-mlabs.com.
